Advisorshares managing director Dan Ahrens said the next White House drug agenda could redraw the map for cannabis and psychedelics, with investors bracing for policy swings that may move markets. Speaking on a business news program, Ahrens outlined how decisions on enforcement, rescheduling, and research could shape two industries already in flux.
The discussion comes as state legalization expands, federal agencies debate classifications, and clinical studies test new treatments for mental health. Ahrens argued that regulatory direction will affect taxes, banking, and capital access for cannabis companies, while psychedelics will hinge on the Food and Drug Administration’s stance and state-level pilots.
Policy Signals And What’s At Stake
Cannabis remains illegal at the federal level even as most states allow medical or adult use. That split has created tax burdens and banking hurdles for operators. Ahrens said any new administration’s approach to enforcement, appointments at the Department of Justice and the Drug Enforcement Administration, and willingness to back congressional fixes could change those realities.
He pointed to two pressure points. First, rescheduling cannabis could relax the tax code treatment that denies standard deductions to plant-touching firms. Second, targeted banking reform could reduce cash handling and borrowing costs. Either step could lift profitability for U.S. operators and exchange-traded funds that hold them.
Cannabis: Rescheduling, 280E, And Banking Access
A move to reclassify cannabis to a less restrictive schedule would not legalize interstate commerce by itself. But it would weaken the Internal Revenue Code Section 280E penalty that inflates effective tax rates. Ahrens noted that even a modest change here could free cash for expansion and debt reduction.
Banking remains another choke point. The lack of federal clarity keeps many lenders on the sidelines and forces companies to rely on higher-cost financing. Ahrens said that stable guidance from federal regulators, or a narrow bill that shields banks, would lower costs and improve safety for workers who now handle large volumes of cash.
Psychedelics: FDA Path And State Experiments
Psychedelics such as psilocybin and MDMA are still classified as Schedule I. Yet the FDA has granted “breakthrough therapy” designations to several trials, signaling potential medical value if safety and efficacy are proven. Ahrens said federal support for research, clear trial standards, and timely reviews will be decisive.
States are also testing new models. Oregon created a licensed psilocybin services program, and Colorado is building a similar system. These programs are limited and do not change federal status. Ahrens suggested that the next administration’s posture on state pilots and clinical studies could either speed or slow investment in clinics, training, and supply chains.
Mixed Messages On Law And Order
Campaign talk often stresses law and order, which can signal tougher drug enforcement. At the same time, past deregulatory moves and a focus on economic growth could support capital access and research. Ahrens said investors should prepare for cross-currents: stricter rhetoric alongside selective steps that ease finance or encourage medical pathways.
Industry voices echo the split view. Patient advocates want access to new treatments for PTSD and depression, while law enforcement groups warn about diversion and public health risks. Without clear federal rules, courts and agencies will continue to shape outcomes case by case.
Market Impact And Investor Watchlist
Stock prices for U.S. cannabis operators have reacted sharply to policy headlines, including past talks of rescheduling and banking reform. Psychedelic developers trade on clinical data and FDA feedback. Ahrens said positioning now depends on policy scenarios, not just near-term earnings.
- Rescheduling that eases 280E could lift cash flow for multi-state operators.
- Narrow banking protections may reduce financing costs and improve safety.
- Clear FDA guidance and supportive agency leadership would aid psychedelic trials.
- Heavier enforcement or delays at federal agencies could stall both sectors.
What Comes Next
The next administration’s appointments at Justice, DEA, HHS, and FDA will set the tone. Ahrens urged attention to early personnel choices, enforcement memos, and any movement on targeted bills in Congress. He also flagged state momentum as a backstop, since more legal markets raise pressure for federal clarity.
For now, cannabis operators are focused on taxes, banking, and compliance, while psychedelic firms seek clinical milestones. Investors will watch for signals on rescheduling, agency guidance, and whether Washington supports research and safer finance even amid tough-on-crime messaging.
The bottom line is simple. Policy clarity could unlock capital and speed medical access. Policy drift could freeze it. The first 100 days will tell which path wins.